Anteris Technologies Showcases Data from 100 Patients Treated with DurAVR® THV at PCR London Valves

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Nov 16 2025

0mins

Source: Globenewswire

Clinical Outcomes of DurAVR THV: Anteris Technologies reported positive 30-day clinical outcomes for the DurAVR THV in 100 patients with severe aortic stenosis and small aortic annuli, showing low mean gradients, no valve-related mortality, and a 97% freedom from moderate or severe prosthesis-patient mismatch.
Technical Success and Safety: The DurAVR THV achieved a 100% technical success rate in the last 50 patient implants, with favorable hemodynamic profiles and no moderate or severe paravalvular leaks, indicating strong safety and effectiveness.
Significance of Prosthesis-Patient Mismatch: The study highlighted the importance of reducing prosthesis-patient mismatch, which is linked to long-term survival and valve failure, particularly in patients with small aortic annuli.
Future Trials and Commercialization: The results contribute to the ongoing EMBARK study and the upcoming PARADIGM Trial, reinforcing confidence in the DurAVR THV's potential for commercialization as a treatment for aortic stenosis.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.